LAB Research completes development of novel drug investigation model

New technologies and partnerships launched to date in 2010 are expected to generate $ 3 to 5 million in annual contracts by 2011

LAB Research Inc. ("LAB Research"), (TSX: LRI), a Canadian-based global non-clinical contract research organization, today announced that it has recently completed development of a novel drug investigation model focused on biodistribution and pharmacokinetic of biologics.

LAB Research's innovative strategy combines its expertise in pharmacology, infusion, surgery and minipigs research and could potentially revolutionize pharmacokinetic assessments of new therapeutic proteins. The new drug investigation model was created with the specific goal of meeting the early non-clinical research needs of pharmaceutical companies developing therapeutic proteins and to facilitate lead compound selection. The new model is being offered for regulatory driven studies complying with Good Laboratory Practices.

"The completion of this novel drug investigation model follows another recently completed research and development program involving real time quantitative pulmonary monitoring of non-human primates using wireless telemetry technology. Both highly specialized programs, once again, clearly demonstrate our leadership in developing innovative scientific solutions for clients", said Luc Mainville, President and Chief Executive Officer of LAB Research. "The launch of novel services and partnerships announced to date in 2010 are meant to help generate new recurrent revenues estimated at $3 to 5 million per year by 2011."